Stephens & Co. Maintains Overweight on 10x Genomics, Raises Price Target to $65
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Stephens & Co. analyst Mason Carrico maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $50 to $65.
Stephens & Co. analyst Mason Carrico maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $50 to $65.